TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05988567

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo candy
Description: consume 2 tablets per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melon and oil olive pressed candy
Description: consume 2 tablets per day
Study: NCT05015036

Intervention type: PROCEDURE
Intervention: ERAS
Description: Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)

Intervention type: PROCEDURE
Intervention: Minimally invasive surgery
Description: Classic Minimally invasive surgery of the lumbar spine
Study: NCT04757155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)
Description: A online psychotherapy designed for patients with advanced and metastatic cancer.
Study: NCT05406700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral, daily, dosage per protocol,4 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resection/Treatment with Niraparib
Description: The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resection/Treatment with Niraparib
Description: The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.
Study: NCT06225973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-925
Description: TL-925 is an eye drop.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05724303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-week neuromuscular training program
Description: Training program consisting of two neuromuscular training sessions per week
Study: NCT05208333

Intervention type: DRUG
Group type: OTHER
Intervention: Albenza 200Mg Tablet
Description: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection
Study: NCT04858308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYC506
Description: YYC506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Active control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYC506 Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Placebo
Description: Placebo
Study: NCT05088499

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study: NCT05946200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow technique in general anesthesia
Description: It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Low flow technique in general anesthesia
Description: It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
Study: NCT06203470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A
Description: Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A
Description: Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: topical Calcineurin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: topical Calcineurin inhibitor
Study: NCT04718870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Study: NCT05766774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-added sugar, high-fat diet
Description: Consist of \<5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-added sugar, high-fat CF diet
Description: Consist of ≥13% kcal from added sugars and the glycemic index will be \>60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
Study: NCT05578274

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + LDRT
Description: SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT alone
Description: SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.
Study: NCT05419024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Treatment Interruption
Description: Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
Study: NCT05669014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Participants will be administered daxdilimab by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daxdilimab
Description: Participants will be administered daxdilimab by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered identically matching placebo by SC injection.
Study: NCT06724887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Strategy Training and Education
Description: Initial training strategies cover Strategic Memory Advanced Reasoning Tactics (SMART), and subsequent training extends the SMART principles to other life-applications such as stress management, sleep, and lifestyle. Virtual and in-person workshops will expand on topics such as stress management, sleep, resilience, and mental well-being, with an emphasis on how practicing and implementing brain healthy strategies can impact everyday life. For faculty/staff, we will also offer interactive workshops on how to create a brain healthy environment and classroom, including ways to implement and provide brain-healthy strategies and resources in their everyday operations involving students.
Study: NCT06727708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tone Your Body BioCircuit Program
Description: Participants in the Tone Your Body group follow a 12-week BioCircuit training programme designed to improve body composition and muscle toning. The programme consists of six total-body strength exercises and two cardio exercises in a circuit format. Each exercise is performed for 45 seconds, followed by a 40-second rest between machines. The endurance exercises are performed for 3 minutes and 35 seconds each. The eccentric phase of each strength exercise is overloaded by 20% to maximise muscle development.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boost Performance BioCircuit Program
Description: Participants in the Boost Performance group follow a 12-week BioCircuit training programme designed to increase strength and endurance. The programme consists of six strength exercises and two cardio exercises, also in a circuit format. Each exercise is performed for 45 seconds, with 40 seconds rest between machines, and the endurance exercises are performed for 3 minutes and 35 seconds. The strength exercises use a viscous resistance mechanism to increase strength and endurance. Participants also undergo performance tests including the jump and reach test, one minute squats and one minute push-ups.
Study: NCT06729008

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes-specific nutrition formula (DSNF)
Description: The diabetes-specific nutrition formula to be used in this study will be Glucerna (Abbott Laboratories). It features an advanced blend of low-glycemic carbohydrates for steady energy release, a dual fiber blend to support digestive health, and a unique lipid blend free from trans fats, cholesterol, and low in saturated fat. Additionally, Glucerna is enriched with 4x more inositol and high levels of trivalent chromium, which contribute to maintaining normal blood glucose levels. It provides 28 essential vitamins and minerals, is low in lactose, and gluten-free, making it a suitable option for various dietary needs. 5 scoops will be mixed in 200 mL of water, and this amounts to 228 calories, with 30.01g of carbohydrates, 10.16g of protein, and 8.70g of fat. This will be given twice, as a breakfast replacement and an afternoon snack replacement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy
Description: Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy
Description: Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome
Study: NCT06180642

Intervention type: OTHER
Intervention: Assessment of soft tissue properties
Description: Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
Study: NCT05556148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otrivine Congestion Relief
Description: 0.1% Nasal Spray (Xylometazoline Hydrochloride)
Study: NCT05102669

Intervention type: OTHER
Intervention: analysis of immunological response
Description: collection and analysis of SARS-CoV2 Spike specific blood cells

Intervention type: OTHER
Intervention: analysis of immunological response
Description: collection and analysis of SARS-CoV2 Spike specific blood cells

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of serum antibodies
Description: analysis of anti-SARS-CoV2 Spike specific antibodies
Study: NCT04994561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Drugs and Nutritional Supplements
Description: Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months.
Study: NCT06410716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valve-regulated pleural drainage system
Description: Patients using valve-regulated pleural drainage system (Ningbo Xinyue Medical Technology Co., Ltd., model AFG31-1) postoperatively.
Study: NCT05946226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC002 injection
Description: three different IMC002 Doses will be escalated in 3+3 design
Study: NCT05695742

Intervention type: OTHER
Intervention: Active Smoking
Description: Being active smoker

Intervention type: OTHER
Intervention: Passive smoker
Description: Being exposed to secondhand smoke
Study: NCT06180642

Intervention type: OTHER
Intervention: Assessment of soft tissue properties
Description: Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound

Intervention type: OTHER
Intervention: Assessment of soft tissue properties
Description: Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound

Intervention type: OTHER
Intervention: Retest assessment of soft tissue properties
Description: Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
Study: NCT05695742

Intervention type: OTHER
Intervention: Non-smoker
Description: Not being an active or passive smoker.
Study: NCT06180642

Intervention type: OTHER
Intervention: Retest assessment of soft tissue properties
Description: Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound

Intervention type: OTHER
Intervention: Retest assessment of soft tissue properties
Description: Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
Study: NCT06432972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehab
Description: Prehab will include 2, one-hour sequential sessions of PR per day as is standard, however this intervention will increase the frequency from 2 days to 4 days per week, for 2 weeks, thus completing 16 sessions of PR prior to surgery. An exercise prescription will be written by the medical director based on initial 6MWD, age, height, weight, and co-morbidities, as is standard of care. Prior to each session, patients are evaluated for symptoms and vital signs are measured. Exercise will include 30 minutes of warm-up and upper and lower extremity resistance training, either against gravity or with resistance bands as appropriate. Exercise will then move to the open gym, where patients utilize endurance equipment of their choosing, such as a treadmill or recumbent bicycle. As with traditional PR, participants will be given online education videos regarding lung health to complete at home, with a supplementary video on breathing techniques to reduce atelectasis from pain.
Study: NCT04761367

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity. Physical Activity program is performed in a group in a gym
Description: The intervention groups will be trained in a gyms under the direct supervision of a graduate trainer. All subjects will be requested to choose an additional third day of the week to carry out at least one of the following activities: walking, cycling or swimming
Study: NCT06238024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Single dose intravenous application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% 100ml
Description: Single dose intravenous application
Study: NCT05757414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored Lighting Intervention (LIT)
Description: The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: An actigraph is a wrist worn device that measures rest and activity patterns
Study: NCT05184348

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrow band Ultraviolet B phototherapy group
Description: 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin group
Description: dose of 0.5-1 mg per kg per day orally for 3 month.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin plus Narrow band Ultraviolet B phototherapy group
Description: Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
Study: NCT05209230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy
Description: Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
Study: NCT05610488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]
Description: Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
Study: NCT04819061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS Active
Description: This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
Study: NCT05357976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
Study: NCT06190106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Psychotherapeutic Intervention)
Description: A psychotherapeutic intervention CBT is given to assess the improvement and betterment in mental health and to assess the reduction of Psychiatric symptoms like depression, anxiety and stress
Study: NCT05050825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient clinical management based on the CDSA strategy
Description: The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
Study: NCT05071638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cord blood mononuclear cells
Description: preterm neonates less than 28 weeks who suffer BPD and also stored cord blood are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg).
Study: NCT05692700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: essential oil application by inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: essential oil application by inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo essential oil